National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
复制标题
DOI：
10.1136/rmdopen-2020-001332
复制
发表时间：
2020-09
期刊：
影响因子：
6.2
通讯作者：
Specker C
中科院分区：
文献类型：
--
作者：
Hasseli R;Mueller-Ladner U;Schmeiser T;Hoyer BF;Krause A;Lorenz HM;Regierer AC;Richter JG;Strangfeld A;Voll RE;Pfeil A;Schulze-Koops H;Specker C
感染严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的炎性风湿病（IRD）患者可能有发展为严重COVID-19病程的风险。免疫调节药物对COVID-19病程的影响尚不清楚。为了收集关于IRD患者中SARS-CoV-2感染的知识，我们在德国大流行开始后不久建立了一个登记处。使用在线问卷（www.COVID19-rheuma.de），于2020年3月30日启动了一个全国性数据库，并获得适当的伦理和数据保护批准，以收集感染SARS-CoV-2的IRD患者的数据。在该登记中，记录了关键的临床和流行病学参数，例如，IRD的诊断、抗风湿治疗、合并症和感染过程。截至2020年4月25日，报告了104例感染SARS-CoV-2的IRD患者的数据（40例男性; 63例女性; 1例不同）。他们中的大多数（45%）被诊断为类风湿性关节炎，59%有一种或多种合并症，42%接受生物疾病缓解抗风湿药物治疗。32%的患者报告住院治疗。三分之二的患者已经康复。不幸的是，6例患者发生了致死性病程。在很短的时间内，建立了一个国家登记处，登记SARS-CoV 2感染的IRD患者。在4周内，记录了104例病例。该登记研究能够在这种新出现的情况下快速生成数据，并更好地了解IRD患者的SARS-CoV 2感染过程，特别关注其免疫调节治疗。这些知识对于及时向医生和IRD患者提供信息很有价值，也将有助于制定在此大流行期间管理IRD患者的指南。
Patients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany. Using an online questionnaire (www.COVID19-rheuma.de), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters—for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection—are documented. Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course. In a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic.
登录
查看更多内容
影响因子：
4.9
作者：
Hsu, Chung-Yuan;Ko, Chi-Hua;Lin, Chun-Yu
通讯作者：
Lin, Chun-Yu
影响因子：
4.7
作者：
Veetil, Bharath Manu Akkara;Myasoedova, Elena;Crowson, Cynthia S.
通讯作者：
Crowson, Cynthia S.
中国武汉市 138 例 2019 新型冠状病毒感染肺炎住院患者的临床特征。
影响因子：
120.7
作者：
Wang, Dawei;Hu, Bo;Peng, Zhiyong
通讯作者：
Peng, Zhiyong
影响因子：
--
作者：
Doran, MF;Crowson, CS;Gabriel, SE
通讯作者：
Gabriel, SE
影响因子：
13.3
作者：
Mikuls, Ted R.;Johnson, Sindhu R.;Saag, Kenneth G.
通讯作者：
Saag, Kenneth G.